William C Jackson1, Ming Tang2, Matthew J Schipper3, Howard M Sandler4, Zachary S Zumsteg4, Jason A Efstathiou5, William U Shipley5, Wendy Seiferheld6, Himanshu R Lukka7, Jean-Paul Bahary8, Anthony L Zietman5, Thomas M Pisansky9, Kenneth L Zeitzer10, William A Hall11, Robert T Dess1, Richard D Lovett12, Alexander G Balogh13, Felix Y Feng14, Daniel E Spratt15,16. 1. Department of Radiation Oncology, University of Michigan, Ann Arbor, MI. 2. University of Michigan, Ann Arbor, MI. 3. Department of Biostatistics, University of Michigan, Ann Arbor, MI. 4. Cedars Sinai Medical Center, Los Angeles, CA. 5. Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 6. NRG Oncology SDMC, Philadelphia, PA. 7. Hamilton Health Sciences, Hamilton, ON, Canada. 8. Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada. 9. Department of Radiation Oncology, Mayo Clinic, Rochester, MN. 10. Einstein Medical Center, Philadelphia, PA. 11. Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI. 12. University of Vermont Medical Center, Burlington, VT. 13. Tom Baker Cancer Centre, Calgary, AB, Canada. 14. Department of Radiation Oncology, University of California San Francisco, San Francisco, CA. 15. Department of Radiation Oncology, University Hospitals, Cleveland, OH. 16. Department of Radiation Oncology, Case Western Reserve University School of Medicine, Cleveland, OH.
Abstract
PURPOSE: Metastasis-free survival (MFS), but not event-free survival, is a validated surrogate end point for overall survival (OS) in men treated for localized prostate cancer. It remains unknown if this holds true in biochemically recurrent disease after radical prostatectomy. Leveraging NRG/RTOG 9601, we aimed to determine the performance of intermediate clinical end points (ICEs) as surrogate end points for OS in recurrent prostate cancer. MATERIALS AND METHODS: NRG/RTOG 9601 randomly assigned 760 men with recurrence after prostatectomy to salvage radiation therapy with 2 years of placebo versus bicalutamide 150 mg daily. ICEs assessed were biochemical failure (BF) per NRG/RTOG 9601 (prostate-specific antigen nadir + 0.3-0.5 ng/mL or initiation of salvage hormone therapy; [BF1]) and NRG/RTOG 0534 (prostate-specific antigen nadir+2 ng/mL; [BF2]), distant metastasis (DM), and MFS (DM or death). Surrogacy was assessed by the Prentice criteria and a two-stage meta-analytic approach (condition one assessed at the patient level with Kendall's τ and condition two assessed by randomly dividing the entire trial cohort into 10 pseudo trial centers and calculating the average R2 between treatment hazard ratios for ICE and OS). RESULTS: BF1, BF2, DM, and MFS satisfied the four Prentice criteria. However, with the two-condition meta-analytic approach, there was strong correlation between MFS and OS (τ = 0.86), moderate correlation between DM and OS (τ = 0.66), and weaker correlation between BF1 (τ = 0.25) or BF2 (τ = 0.40) and OS. Similarly, for condition two, the treatment effect of antiandrogen therapy on MFS and OS were correlated (R2 = 0.67), but this was not true for BF1 (R2 = 0.09), BF2 (R2 = 0.12), or DM (R2 = 0.18) and OS. CONCLUSION: MFS is also a strong surrogate for OS in men receiving salvage radiation therapy for recurrence after prostatectomy. Caution should be used when inferring survival benefit from effects on BF in biochemically recurrent prostate cancer. Lack of comorbidity data did not allow us to assess whether BF in men with no/minimal comorbidity could serve as a surrogate for OS.
PURPOSE: Metastasis-free survival (MFS), but not event-free survival, is a validated surrogate end point for overall survival (OS) in men treated for localized prostate cancer. It remains unknown if this holds true in biochemically recurrent disease after radical prostatectomy. Leveraging NRG/RTOG 9601, we aimed to determine the performance of intermediate clinical end points (ICEs) as surrogate end points for OS in recurrent prostate cancer. MATERIALS AND METHODS: NRG/RTOG 9601 randomly assigned 760 men with recurrence after prostatectomy to salvage radiation therapy with 2 years of placebo versus bicalutamide 150 mg daily. ICEs assessed were biochemical failure (BF) per NRG/RTOG 9601 (prostate-specific antigen nadir + 0.3-0.5 ng/mL or initiation of salvage hormone therapy; [BF1]) and NRG/RTOG 0534 (prostate-specific antigen nadir+2 ng/mL; [BF2]), distant metastasis (DM), and MFS (DM or death). Surrogacy was assessed by the Prentice criteria and a two-stage meta-analytic approach (condition one assessed at the patient level with Kendall's τ and condition two assessed by randomly dividing the entire trial cohort into 10 pseudo trial centers and calculating the average R2 between treatment hazard ratios for ICE and OS). RESULTS: BF1, BF2, DM, and MFS satisfied the four Prentice criteria. However, with the two-condition meta-analytic approach, there was strong correlation between MFS and OS (τ = 0.86), moderate correlation between DM and OS (τ = 0.66), and weaker correlation between BF1 (τ = 0.25) or BF2 (τ = 0.40) and OS. Similarly, for condition two, the treatment effect of antiandrogen therapy on MFS and OS were correlated (R2 = 0.67), but this was not true for BF1 (R2 = 0.09), BF2 (R2 = 0.12), or DM (R2 = 0.18) and OS. CONCLUSION: MFS is also a strong surrogate for OS in men receiving salvage radiation therapy for recurrence after prostatectomy. Caution should be used when inferring survival benefit from effects on BF in biochemically recurrent prostate cancer. Lack of comorbidity data did not allow us to assess whether BF in men with no/minimal comorbidity could serve as a surrogate for OS.
Authors: Wanling Xie; Meredith M Regan; Marc Buyse; Susan Halabi; Philip W Kantoff; Oliver Sartor; Howard Soule; Donald Berry; Noel Clarke; Laurence Collette; Anthony D'Amico; Richard De Abreu Lourenco; James Dignam; Mario Eisenberger; Nicholas James; Karim Fizazi; Silke Gillessen; Yohann Loriot; Nicolas Mottet; Wendy Parulekar; Howard Sandler; Daniel E Spratt; Matthew R Sydes; Bertrand Tombal; Scott Williams; Christopher J Sweeney Journal: J Clin Oncol Date: 2020-06-18 Impact factor: 44.544
Authors: James W Denham; Allison Steigler; Chantelle Wilcox; David S Lamb; David Joseph; Chris Atkinson; John Matthews; Keen-Hun Tai; Nigel A Spry; David Christie; Paul S Gleeson; Peter B Greer; Catherine D'Este Journal: Lancet Oncol Date: 2008-10-15 Impact factor: 41.316
Authors: Matthew R Smith; Fred Saad; Simon Chowdhury; Stéphane Oudard; Boris A Hadaschik; Julie N Graff; David Olmos; Paul N Mainwaring; Ji Youl Lee; Hiroji Uemura; Angela Lopez-Gitlitz; Géralyn C Trudel; Byron M Espina; Youyi Shu; Youn C Park; Wayne R Rackoff; Margaret K Yu; Eric J Small Journal: N Engl J Med Date: 2018-02-08 Impact factor: 91.245
Authors: Maha Hussain; Karim Fizazi; Fred Saad; Per Rathenborg; Neal Shore; Ubirajara Ferreira; Petro Ivashchenko; Eren Demirhan; Katharina Modelska; Andrew Krivoshik; Cora N Sternberg Journal: N Engl J Med Date: 2018-06-28 Impact factor: 91.245
Authors: Michael E Ray; Kyounghwa Bae; Maha H A Hussain; Gerald E Hanks; William U Shipley; Howard M Sandler Journal: J Natl Cancer Inst Date: 2009-02-10 Impact factor: 13.506
Authors: William C Jackson; Krithika Suresh; Vasu Tumati; Steven G Allen; Robert T Dess; Simpa S Salami; Arvin George; Samuel D Kaffenberger; David C Miller; Jason W D Hearn; Shruti Jolly; Rohit Mehra; Brent K Hollenbeck; Ganesh S Palapattu; Matthew Schipper; Felix Y Feng; Todd M Morgan; Neil B Desai; Daniel E Spratt Journal: Eur Urol Date: 2018-01-03 Impact factor: 20.096
Authors: Trevor J Royce; Ming-Hui Chen; Jing Wu; Marian Loffredo; Andrew A Renshaw; Philip W Kantoff; Anthony V D'Amico Journal: JAMA Oncol Date: 2017-05-01 Impact factor: 31.777
Authors: Wanling Xie; Meredith M Regan; Marc Buyse; Susan Halabi; Philip W Kantoff; Oliver Sartor; Howard Soule; Noel W Clarke; Laurence Collette; James J Dignam; Karim Fizazi; Wendy R Paruleker; Howard M Sandler; Matthew R Sydes; Bertrand Tombal; Scott G Williams; Christopher J Sweeney Journal: J Clin Oncol Date: 2017-08-10 Impact factor: 44.544
Authors: Karim Fizazi; Neal Shore; Teuvo L Tammela; Albertas Ulys; Egils Vjaters; Sergey Polyakov; Mindaugas Jievaltas; Murilo Luz; Boris Alekseev; Iris Kuss; Christian Kappeler; Amir Snapir; Toni Sarapohja; Matthew R Smith Journal: N Engl J Med Date: 2019-02-14 Impact factor: 176.079